Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and its 45%-owned subsidiary, Sapu Nano (US) LLC, announced that the independent Safety Review Committee has completed its review of the initial three-patient safety cohort in the ongoing Phase 1b SP-03-B101 trial of Sapu003. The committee found no dose-limiting toxicities and recommended advancement to the next planned dose level. The company also disclosed plans to expand the study into Europe with additional clinical sites to broaden patient access and support enrollment.
The positive safety review marks a critical milestone for Sapu003, an intravenous formulation of everolimus delivered via Oncotelic’s Deciparticle nanomedicine platform. The company said the clinical milestone follows the publication of peer-reviewed research describing the scientific foundation of the Deciparticle platform and the formulation, supporting its scalable manufacturing capabilities, stability, and preclinical antitumor activity while reinforcing the ongoing clinical development program.
This development is significant because it validates the safety profile of Sapu003 in patients, allowing the trial to proceed to higher doses that may be more effective. For patients with solid tumors who have limited treatment options, this could represent a new therapeutic approach. The planned European expansion also suggests the company is positioning for broader global clinical development, which could expedite regulatory approvals and market access.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company benefits from the portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. Oncotelic also develops PDAOAI, its proprietary AI platform for drug discovery, lab automation, and AI-assisted GMP manufacturing, which underpins ongoing joint development work with TechForce Robotics.
The implications of this announcement are multifaceted. For the biopharmaceutical industry, it underscores the potential of nanomedicine platforms to improve drug delivery and reduce toxicity. For investors, the positive safety review and dose escalation may signal reduced risk and a clearer path to later-stage trials. For patients, particularly those with rare cancers, Sapu003 could offer a new treatment option if efficacy is confirmed in subsequent cohorts.
As the trial advances, all eyes will be on efficacy data. The company’s commitment to expanding into Europe suggests confidence in the drug’s potential. The full press release is available at https://ibn.fm/sBbID. For more information about Oncotelic, visit www.oncotelic.com.
This news matters because it demonstrates progress in a clinical program that could address significant unmet medical needs. The safety review and planned expansion indicate momentum that could influence the trajectory of cancer treatment and the company’s value.
